We studied the effect of 30mg of prednisolone on 29 Japanese patients with chronic ob structive pulmonary disease (COPD). The mean value of the baseline forced expiratory volume in one second (FEVi; mean±SEM) was 1.14±0.12/ (46.9±3.9% pred) and the FEVx following the steroid trial was 1.30 ± 0.12/ (53.7 ± 4.3% pred). Post-trial FEVx -baseline FEVi/predicted FEV! was 6.8 ± 1.9%. Five patients (17%) had more than a 15% increase in FEVi as a percentage of predicted FEVi. Post-trial FEV^baseline FEV! was 117.3 ± 4.3% , and 12 patients (41%) had more than a 20% increase in FEVi after the trial. Acute bronchodilator response to j3-agonist correlated positively with the response to corticosteroid. Baseline spiro metries, blood eosinophil counts, serum IgE levels, sputum eosinophil counts, family history of asthma, and history of paroxysmal dyspnea did not vary across responders and non-responders. Patients with severe COPD should be treated to achieve the best possible pulmonary functions indicated by a steroid trial within the limit of acceptable levels of adverse effects.
Intr oduction
The American Thoracic Society defines chronic obstructive pulmonary disease (COPD) as a disorder characterized by abnormal tests of expiratory flow that do not change markedly over periods of several months of observation (1). On the other hand, asthma is a clinical syndrome characterized by increased responsiveness of the tracheobronchial tree to a variety of stimuli (1). Asthma should be distinguished from COPD but the diagnosis is occasionally confusing because of its overlap with COPD and the separation of these overlap patients may be arbitrary and difficult, and from a clinical stand point probably not always important (1). One hypothesis holds that asthma and COPD are different expressions of the same disease (2). Emphysema is the most important disorder incorporated in COPD. Emphysematous change may follow chronic inflammation of the peripheral airways, and recently, chronic eosinophilic inflammation of the airways has been thought to contribute to the pathogenesis of asthma. From these viewpoints, COPD and asthma may have airway inflammation as a common basic process (3).
The role of corticosteroids in the treatment of COPD is still controversial, although their role in asthma therapy is well established. Some patients with COPD who do not respond to routine bronchodilator therapy do seem to respond to corticosteroids, and some of the responders may benefit from such therapy. In 1978, Sahn reviewed studies evaluating the efficacy of corticosteroid therapy in treating COPD (4). Indicating the need for controlled studies with an accurate selection of patients, Sahn proposed a steroid trial in patients who did not improve with routine bronchodilator therapy (4). To improve the quality of life of patients with COPD whose symptoms are severe enough to restrict their daily activity despite routine bronchodilator therapy, physicians must strive to maintain the highest level of pulmonary function which can be determined by a steroid trial within the limits imposed by side effects. This treatment may necessitate the use of systemic corti costeroids with deliberate titration. Steroid responders with COPD may also respond to large doses of inhaled steroids, which have few adverse effects systemically. To date, there are no reports of steroid trials in Japanese patients. The purpose of this study is to evalu ate a steroid trial in 29 Japanese patients with COPD, using 30mg of prednisolone for 2 weeks.
Patients and Methods
Twenty-nine patients with COPD, who had a history of smoking and a FE\Vforced vital capacity (FVC) of less than 70% after inhalation of ^-agonist and anti cholinergics, were enrolled. None showed chest X-ray findings suggestive of other specific diseases. Twenty-seven were male. All were considered clinically stable at the start of the trial. Patients with a clinical diagnosis of asthma, pneumoconiosis, diffuse panbronchiolitis, or sequelae of pulmonary tuberculosis, were excluded. No patients received oral or inhaled corticosteroids in the two weeks prior to the trial. All were treated with regular inhalation of bronchodilator. Inhaled salbutamol was used in 20 cases and ipratropium bromide in all cases. In 12 cases, slow-releasing theophylline was also administrated. Before the start of the trial, blood eosinophil counts, serum IgE levels, sputum eosinophil counts, complete family and personal histories, and acute bronchodilator response were obtained. Sputum examination was done using three successive early morning sputa. Those who had sputa with more than 10% eosinophils on at least 2 occasions, or with more than 20% eosinophils on at least one occasion were considered to have sputum eosinophilia. FEVX and FVC were measured before and 15 minutes after inhalation of 10mg metaproterenol from a DeVilbiss nebulizer, and acute bronchodilator response was obtained from these data. Baseline FEVX and FVC were collected after inhalation of ^-agonist and ipratropium from a metered dose inhaler on day 0. Then 30mg of prednisolone was administered daily from day 1 for 14 days, and on day 14, post-trial FEVi and FVC were collected following inhalation of /3-agonist and ipratropium. Baseline treatment with ^-agonists, anticholinergics, and in some cases theophyl line was maintained at the same level throughout the trial period. Spirometry was done by the same physician using an AS-600 spirometer (Minato Medical Co. Ltd) which was calibrated every morning. The best result of three successive measurements was used to determine FEVi and FVC. Predicted value for FEVi was that of Japan Society of Chest Diseases. The data were analyzed using Student's t-test and Fischer's exact probability test. Results
Baseline patient data Mean age of the 29 patients was 64.2 years (50-76 years). Baseline FEVX was 1.14±0.12/ (46.9±3.9% pred, mean ± SEM, Table 1 ).
Responses to prednisolone Post-trial FEVybaseline FEVX was 117.3 ±4.3%, and 12 patients (41%) had more than a 20% increase in FEVX following the trial. Post-trial FEVX -baseline FEVi/predicted FEVx was 6.8± 1.9%. Five patients (17%) had more than a 15% increase in FEVx as a per centage of predicted FEVx (Fig. 1) . The mean post-trial FEVx was 1.30±0.12L (53.7±4.3% pred), which was significantly larger than the mean baseline FEVX (p<0.01,. Fig. 2 ). n=14 (48%) n=9 (31%) n=5 (17%) Post FEV!.-post-trial FEV^ base FE\V baseline FEV1? ** Shapiro (6), *2 Nisar (5), *3 Turton.
Four types of steroid response were evaluated in the present patient population (Table 2 ): 1) Of 29 patients, 12.(41%) had more than a 20% increase in FEVi following the trial. 2) Nine patients (31%) were identified as responders when response was defined as a post-trial FEVi/baseline FEVx of more than 115% and an absolute change in FEVX of more than 0.2/, which Nisar et al proposed as a good criterion for evaluating acute bronchodilator response (5). 3) Fourteen patients (48%) were considered re sponders when we used the criterion of Shapiro and Campbell (6), of a post-trial FEVybaseline FEVjl of more than 115%, or a post-trial FVC/baseline FVC of more than 120%. 4) Five patients (17%) had more than a 15% increase in FEVi as the percentage of predicted FEVx.
Relationship between baseline characteristics and the response to corticosteroids Baseline FEVi did not correlate with (post-trial FEVx -baseline FEVx)/predicted FEVx or post-trial FEVi/baseline FEVx. The responders, defined according to any of the above criteria, did not differ significantly from non-responders in blood eosinophil counts or serum IgE levels. There,was also no difference between responders and non-responders in the proportion of patients having a past history of paroxysmal dyspnea or a family history of asthma. Patients with sputum eosinophilia did have a greater tendency to respond to corticosteroids, but this did not reach statistical signifi cance (Table 3) . Acute bronchodilator response, expressed as (postbronchodilator FEVi -prebronchodilator FEV^/predicted FEVi, correlated strongly with the response to corticosteroids expressed as (post-trial FEVi -baseline FEV^/predicted FEVj (r=0.689, p < 0.01, Fig. 3 ). When positive bronchodilator or corti costeroid responses were defined as more than a 15% increase in FEV2 as the percentage of the predicted FEVX to inhaled metaproterenol or systemic prednisolone respectively, bronchodilator response predicted cortico steroid response with a positive predictive value of 75% , a negative predictive value of 91% , a sensitivity of 60% and a specificity of 96%. Discussion
With the expansion in the aged population, the number of patients with COPD is increasing in Japan, and the treatment of patients whose symptoms are severe despite routine bronchodilator therapy, has become a critical problem. Subsequent to Sahn's call for a steroid trial (4), a number of trials have been executed in Europe and North America, and various results have been reported. Callahan et al completed a meta-analysis of the English language literatures and concluded that stable COPD patients receiving oral corticosteroid therapy experienced a 20% or greater improvement in baseline FEV1? appro ximately 10% more often than similar patients receiving a placebo (7) . However, there have been no such reports on Japanese patients, though there may well be racial differences in the effects of corticosteroids on COPD. When positive bronchodilator or corticosteroid responses are defined as more than a 15% increase in FEV] over the predicted FEV^ the bronchodilator response predicts corticosteroid response with a positive predictive value of 75% , a negative predictive value of 91%, a sensitivity of 60%, and a specificity of 96%.
be due, at least in part, to differences in entry criteria and the definition of response. Exclusion of asthmatic patients or a strict definition of corticosteroid response will makes the number of steroid-responders appear small. For practical reasons, we defined patients as having COPD when air flow limitation was not fully reversed by routine bronchodilator therapy. Although existence of sputum eosinophilia or elevated antibody titers against fungi in an enzyme-linked immunosorbent assay (ELISA) may favor the diagnosis of difficult chronic asthma, these do not exclude the diagnosis of COPD, and ELISA for fungi was not performed in this study. Taking the adverse effect of systemic corticosteroid into account, it is recommended to attempt to avoid unnecessary administration of steroid by using a restric tive definition of response, although not so restrictive as to preclude an opportunity to improve the quality of life of patients who may benefit from corticosteroid therapy. In general, the proportion of steroid responders was smaller in the reports using the response definition that required improvement to be significantly greater than the variation in baseline or placebo periods (8-10), and larger in the studies using the definition that simply In the present study, the response rate varied from 17% to 48% depending on the response definition. Eliasson et al (10) reviewed other reports on steroid trials and found that the response rate correlates negatively with baseline FEVi. They suggest that the patients in these series were severe cases and not representative of patients with COPD as a whole (10). However, since a steroid trial is indicated in patients who do not improve with routine bronchodilator therapy, patients in the trial may have a low FEVi. Definition of the response to steroids as more than a 15% increase in FEVi as a percentage of predicted FEVx, seems to be too limiting to include those with severe air flow limitation, yet it is for those very same patients with severe COPD that precise estimations of corticosteroid efficacy are most important.
On the other hand, 48% of patients in the present study responded to corticosteroids, using the Shapiro definition, and this was thought to be an overestimation of the response to corticosteroids. The American Thoracic Society recommends that more than a 15% increase in FEVi stand as the criterion for positive acute bron chodilator response (17), and this definition has been widely applied in the evaluation of other medications. However, in the case where baseline FEVi is a liter or less, a 15% increase in FEVi is less than the coefficient of reproducibility in a spirometer. To correct such errors, Nisar et al (5) used the criterion of a rise in FEVx of at least 15% from the baseline value, in addition to an absolute increase in FEVx of at least 0.2 /. According to this definition, 30% of patients in the present study responded to systemic corticosteroids. Clearly, it is very difficult to choose one response definition that is appropriate for all patients with various baseline FEVi values. It has been reported that the bronchodilator response to /3-agonist (ll, 14) or sputum eosinophilia (ll) corre lates with the response to corticosteroids. In our study, the acute bronchodilator response to /3-agonist correlated with the response to prednisolone, and when more than a 15% change in FEVx as a percentage of predicted FEVi was the definition of a positive response, the response to inhaled 10mg metaproterenol predicted the response to systemic 30mg prednisolone with com paratively good sensitivity and specificity. The presence of sputum eosinophilia tended to correlate with a positive response to corticosteroids, but some patients did not expectorate deep sputum, thereby limiting sputum examination as a predictor of steroid response (13).
Corticosteroid including the inhaled form has no role in the treatment of those who do not respond to oral corticosteroids. Evans et al reported that systemic 5 mg prednisone does not improve chronic airflow limitation in patients with COPD (18). In their retrospective series (19, 20), Postma et al showed that long-term oral admini stration of 10-15 mg of prednisolone might slow down airway obstruction, but long-term oral corticosteroid treatment was abandoned because of the side effects and the introduction of inhaled steroids in many patients. Stokes et al suggested that administration of more than 20mg of prednisolone is necessary to maintain the re sponse obtained by a steroid trial (9). In patients with advanced COPD who respond to oral corticosteroids, physicians must consider the indication and dosage of systemic medication. When systemic steroids are indicated, the lowest effective dose should be used, and alternate day therapy is preferable where possible. Some patients with COPD who respond to a steroid trial may benefit from large-dose inhaled cortico steroids (16, 21, 22) and in these cases inhaled steroids is preferred. However, the efficacy of alternate day therapy or inhaled steroids has not been established and further research is needed. In conclusion, of 29 patients with COPD, 5 patients showed more than a 15% increase in FEVi as a percentage of predicted FEVl7 and 14 patients showed more than a 15% increase in FEVx and/or more than a 20% increase in FVC by oral administration of 30mg of prednisolone for 14 days. Although it is difficult to predict exactly the response to corticosteroids from pretrial characteristics, the acute bronchodilator response to inhaled /3-agonist correlates positively with the response to corticosteroids. For patients with advanced COPD whose symptoms are severe enough to live a useful life, physicians should strive to maintain the best pulmonary function obtained from a steroid trial, while staying within the limits of acceptability with respect to side effects. 
